1
|
Gay L, Desquiret-Dumas V, Nagot N, Rapenne C, Van de Perre P, Reynier P, Molès JP. Long-term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved. J Med Virol 2024; 96:e29886. [PMID: 39246064 DOI: 10.1002/jmv.29886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 07/26/2024] [Accepted: 08/13/2024] [Indexed: 09/10/2024]
Abstract
Mitochondria are vital for most cells' functions. Viruses hijack mitochondria machinery for misappropriation of energy supply or to bypass defense mechanisms. Many of these mitochondrial dysfunctions persist after recovery from treated or untreated viral infections, particularly when mitochondrial DNA is permanently damaged. Quantitative defects and structural rearrangements of mitochondrial DNA accumulate in post-mitotic tissues as recently reported long after SARS-CoV-2 or HIV infection, or following antiviral therapy. These observations are consistent with the "hit-and-run" concept proposed decades ago to explain viro-induced cell transformation and it could apply to delayed post-viral onsets of symptoms and advocate for complementary supportive care. Thus, according to this concept, following exposure to viruses or antiviral agents, mitochondrial damage could evolve into an autonomous clinical condition. It also establishes a pathogenic link between communicable and non-communicable chronic diseases.
Collapse
Affiliation(s)
- Laetitia Gay
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, Etablissement Français du Sang, University of Antilles, Montpellier, France
| | - Valérie Desquiret-Dumas
- Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France
- MITOVASC Research Unit, CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Nicolas Nagot
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, Etablissement Français du Sang, University of Antilles, Montpellier, France
| | - Clara Rapenne
- Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France
- MITOVASC Research Unit, CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Philippe Van de Perre
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, Etablissement Français du Sang, University of Antilles, Montpellier, France
| | - Pascal Reynier
- Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France
- MITOVASC Research Unit, CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Jean-Pierre Molès
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, Etablissement Français du Sang, University of Antilles, Montpellier, France
| |
Collapse
|
3
|
Ortiz-Gracia A, Ríos M, Tobías E, Noguera-Julian A, García-García FJ, Cantó-Santos J, Valls-Roca L, Garrabou G, Grau JM, Cardellach F, Sánchez E, Morén C, Fortuny C. Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir. Arch Dis Child 2022; 107:686-691. [PMID: 35288419 PMCID: PMC9209682 DOI: 10.1136/archdischild-2021-322996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 02/17/2022] [Indexed: 11/15/2022]
Abstract
BACKGROUND Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Similar anti-HIV drugs have been associated with mitochondrial toxicity but this has never been explored in CMV. OBJECTIVE To determine the potential mitochondrial toxicity profile at the genetic, functional and biogenesis level in peripheral blood mononuclear cells from a cohort of newborns and infants with symptomatic congenital CMV infection (treated with valganciclovir, untreated and uninfected controls). DESIGN Longitudinal, observational and controlled study. SETTING AND PATIENTS Subjects were recruited at the tertiary referral Hospital Sant Joan de Déu and experiments were conducted at IDIBAPS-Hospital Clínic of Barcelona, Spain. CMV-infected newborns underwent comprehensive monthly clinical follow-up. METHODS Mitochondrial parameters, audiometry and neurological assessment were measured at baseline, 3-6 and 12 months after inclusion in the study. The Kruskal-Wallis test for k-independent samples and Friedman tests for repeated measurements were applied. RESULTS Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). CONCLUSIONS No evidence of mitochondrial toxicity was found in infants treated with valganciclovir for congenital CMV.
Collapse
Affiliation(s)
- Alba Ortiz-Gracia
- Pompeu Fabra University, Barcelona, Spain,Universitat Autònoma de Barcelona, Barcelona, Spain
| | - María Ríos
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Ester Tobías
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Antoni Noguera-Julian
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain,Red de Investigación Translacional en Infectología Pediátrica RITIP, Madrid, Spain
| | - Francesc Josep García-García
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Judith Cantó-Santos
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Laura Valls-Roca
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Glòria Garrabou
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Josep Maria Grau
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Francesc Cardellach
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Cellex, Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Emilia Sánchez
- Blanquerna School of Health Science, Ramon Llull University, Barcelona, Spain
| | - Constanza Morén
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain .,Cellex, Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain.,Internal Medicine Department, Hospital Clínic of Barcelona HCB, Barcelona, Spain
| | - Clàudia Fortuny
- Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Sant Joan de Déu, Barcelona, Spain,Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain,Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain,Red de Investigación Translacional en Infectología Pediátrica RITIP, Madrid, Spain
| |
Collapse
|